• Appointment strengthens BioInvent’s presence and strategy in the US
• Mr Robinson brings broad experience from the US and global financial markets
• BioInvent is in a pivotal stage of development with upcoming important data readouts from three of its six antibody programs around year-end 2024, and an additional seven major data readouts expected during 2025 from four different clinical assets.

Lund, Sweden and Boston, US – December 3, 2024 – BioInvent International AB (“BioInvent”) (Nasdaq Stockholm: BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, today announces the appointment of Ashley Robinson as SVP Strategy & Finance, effective as of today. In this role, Mr. Robinson will spearhead efforts to strengthen BioInvent’s presence and strategy in the US.

Ashley Robinson is an accomplished biotechnology business leader and joins BioInvent with 25 years in capital markets and corporate strategy experience. Most recently, he served as Managing Director at LifeSci Advisors, where he established a Life Sci office in Boston, advising key clients in the healthcare sector. Prior roles have been healthcare product specialist, sector head at Guggenheim Securities, Managing Director and Senior Partner at Leerink Partners, Vice President at Lehman Brothers in the ECM division.

"We are delighted to welcome Ashley as our SVP Strategy & Finance and we are looking forward to benefiting from his experience and expertise in healthcare financing and biotechnology consulting," said Martin Welschof, Chief Executive Officer of BioInvent. "Ashley will be based in the US where we are planning to expand BioInvent's presence as part of the strategic development of our company and the continued advancement of our unique immuno-oncology pipeline."

"It is a great privilege to become part of the BioInvent team and to join the efforts in the discovery and development of new and innovative cancer therapies," said Ashley Robinson, SVP Strategy & Finance of BioInvent. "The company is in a strong position with a robust and highly differentiated clinical pipeline, and I am excited to be part of this new phase of growth and development."

About BioInvent
BioInvent International AB (Nasdaq Stockholm: BINV) is a clinical-stage biotech company that discovers and develops novel and first-in-class immuno-modulatory antibodies for cancer therapy, with currently five drug candidates in six ongoing clinical programs in Phase 1/2 trials for the treatment of hematological cancer and solid tumors. The Company's validated, proprietary F.I.R.S.T™ technology platform identifies both targets and the antibodies that bind to them, generating many promising new immune-modulatory candidates to fuel the Company's own clinical development pipeline and providing licensing and partnering opportunities.

The Company generates revenues from research collaborations and license agreements with multiple top-tier pharmaceutical companies, as well as from producing antibodies for third parties in the Company's fully integrated manufacturing unit. More information is available at www.bioinvent.com. Follow us on the social media platform X: @BioInvent.

For further information, please contact:
Cecilia Hofvander, Senior Director Investor Relations
Phone: +46 (0)46 286 85 50
Email: cecilia.hofvander@bioinvent.com

BioInvent International AB (publ)
Co. Reg. No. Org nr: 556537-7263
Visiting address: Ideongatan 1
Mailing address: 223 70 LUND
Phone: +46 (0)46 286 85 50
www.bioinvent.com

The press release contains statements about the future, consisting of subjective assumptions and forecasts for future scenarios. Predictions for the future only apply as the date they are made and are, by their very nature, in the same way as research and development work in the biotech segment, associated with risk and uncertainty. With this in mind, the actual outcome may deviate significantly from the scenarios described in this press release.